PHILADELPHIA, PA — EpiVario, Inc. has announced the addition of Chris Cashman as an independent director to its Board of Directors. Known for his extensive leadership in the pharmaceutical and biotechnology sectors, Cashman brings a wealth of experience to the company.
Chris Cashman’s career spans several decades, during which he has held various executive roles, including CEO positions in the biopharmaceutical industry. His expertise encompasses strategic planning, product development, and commercialization, which are crucial as EpiVario seeks to expand its portfolio of proprietary drugs. “Chris has already provided valuable insight as an advisor to EpiVario, and we are thrilled to expand his role as a Board member,” stated Thomas Kim, CEO of EpiVario.
Previously serving as a Board Observer, Cashman has been a consultant to EpiVario for several years. His transition to a full board member signifies a deeper involvement in guiding EpiVario’s strategic growth and innovation. Cashman expressed his enthusiasm about joining the board, emphasizing his long-standing relationship with Thomas Kim and his commitment to advancing EpiVario’s mission.
The board also includes representation from the University of Pennsylvania, with Dr. Chen serving as a Board Observer. Dr. Chen is an Associate Director at PCI Ventures, which supports emerging companies like EpiVario that leverage university-developed technologies. Her move to observer status aligns with the university’s interest in maintaining oversight while allowing for dynamic leadership changes.
The appointment of Chris Cashman signals EpiVario’s dedication to enhancing its leadership team as it continues to push the boundaries of drug development in the biotech sector. With his seasoned perspective, the company is well-positioned to drive forward its ambitious goals and deliver impactful solutions for patients with serious health conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.